98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study

E Ahn,M Rothe,S Halabi,M.K Hameed,P.K Mangat,J.R Bauman,A.D Baron,E.S Yang,P.J Gold,E Garrett-Mayer,R.L Schilsky,A.S Balmanoukian,G.N Grantham,T Al Baghdadi,K.F Mileham,S.F Powell,F Meric-Bernstam,J.C Krauss,R O'Lone,R Thota

doi:10.1016/j.annonc.2022.07.130

98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study

E Ahn, M Rothe + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.130

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 4	License type: publisher-specific-oa

#Targeted Agent And Profiling Utilization Registry #Profiling Utilization Registry + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with BRCA1/2 mut treated with O are reported.

Full Text